CLINICAL TRIALS PROFILE FOR ZYCLARA

All Clinical Trials for ZYCLARA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01229319 ↗	Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses	Unknown status	Graceway Pharmaceuticals, LLC	Phase 4	2010-10-01	Actinic keratoses (AK) are common cutaneous lesions associate with chronic ultraviolet radiation exposure. While most authorities consider AK as a pre-malignant lesion, some consider it as an incipient squamous cell carcinoma (SCC). In addition, the skin around clinically obvious AK lesions has been subject to the same chronic ultraviolet exposure, resulting in genetic damage and mutations, resulting in "field cancerization." Subclinical AKs may progress to clinical AKs, or even de novo invasive SCCs. Among the current therapies for the treatment of AK are excisional surgery, cryosurgery, electrodessication and curettage, topical chemotherapy and light therapies. With cryotherapy, treated lesion clearance rates at 3 months post-treatment after double-freeze thaw cryotherapy has been reported to be around 76-88%; Overall lesion clearance rate at approximately 5 months post-cryosurgery has been reported to be 35-51%. Imiquimod is a topical immune response modifier and a 5% formulation has been approved for the treatment of AKs in the US as a 2x/week for 16 week regimen and in Europe as a 3x/week for 4 week regimen for 1 or 2 courses of therapy. Topical imiquimod treatment may also reduce subclinical lesions in the treatment area, resulting in fewer "new" AK lesions developing over the same period of time when compared to focal treatment. In a comparison of cryosurgery versus imiquimod for the treatment of AKs, Krawtchenko et al reported initial complete clearance rates of 68 and 85% by clinical assessment, respectively. However, the treatment field sustained clearance rate was 4% versus 73%, respectively. Tan et al reported that while application of imiquimod or vehicle following cryosurgery resulted in comparable target AK clearance rates at 12 weeks of 79% versus 76%, respectively, the imiquimod group had fewer total AKs and fewer subclinical AKs. Imiquimod cream at a concentration of 3.75% has been found in Phase 3 studies to be superior to placebo cream with respect to clearance of AKs using a regimen of up to 2 packets (250 mg of cream per packet, 500 mg total) applied daily to the entire face (approximately 200 cm2) for two 2-week treatment cycles separated by a 2-week no-treatment period. This study aims to examine the benefit of cryotherapy in combination with imiquimod 3.75% compared to cryotherapy alone.
NCT01229319 ↗	Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses	Unknown status	Frankel, Amylynne, M.D.	Phase 4	2010-10-01	Actinic keratoses (AK) are common cutaneous lesions associate with chronic ultraviolet radiation exposure. While most authorities consider AK as a pre-malignant lesion, some consider it as an incipient squamous cell carcinoma (SCC). In addition, the skin around clinically obvious AK lesions has been subject to the same chronic ultraviolet exposure, resulting in genetic damage and mutations, resulting in "field cancerization." Subclinical AKs may progress to clinical AKs, or even de novo invasive SCCs. Among the current therapies for the treatment of AK are excisional surgery, cryosurgery, electrodessication and curettage, topical chemotherapy and light therapies. With cryotherapy, treated lesion clearance rates at 3 months post-treatment after double-freeze thaw cryotherapy has been reported to be around 76-88%; Overall lesion clearance rate at approximately 5 months post-cryosurgery has been reported to be 35-51%. Imiquimod is a topical immune response modifier and a 5% formulation has been approved for the treatment of AKs in the US as a 2x/week for 16 week regimen and in Europe as a 3x/week for 4 week regimen for 1 or 2 courses of therapy. Topical imiquimod treatment may also reduce subclinical lesions in the treatment area, resulting in fewer "new" AK lesions developing over the same period of time when compared to focal treatment. In a comparison of cryosurgery versus imiquimod for the treatment of AKs, Krawtchenko et al reported initial complete clearance rates of 68 and 85% by clinical assessment, respectively. However, the treatment field sustained clearance rate was 4% versus 73%, respectively. Tan et al reported that while application of imiquimod or vehicle following cryosurgery resulted in comparable target AK clearance rates at 12 weeks of 79% versus 76%, respectively, the imiquimod group had fewer total AKs and fewer subclinical AKs. Imiquimod cream at a concentration of 3.75% has been found in Phase 3 studies to be superior to placebo cream with respect to clearance of AKs using a regimen of up to 2 packets (250 mg of cream per packet, 500 mg total) applied daily to the entire face (approximately 200 cm2) for two 2-week treatment cycles separated by a 2-week no-treatment period. This study aims to examine the benefit of cryotherapy in combination with imiquimod 3.75% compared to cryotherapy alone.
NCT01502020 ↗	A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses	Completed	Actavis Mid-Atlantic LLC	N/A	2011-02-01	Zyclara™ (imiquimod) Cream, 3.75% is approved by the FDA for the treatment of actinic keratoses on the full face or balding scalp. Zyclara is applied once daily for two, 2-week treatment cycles separated by a 2-week no treatment applied interval. A generic imiquimod cream, 3.75% has been developed by Actavis Mid-Atlantic LLC for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the full face or balding scalp. The current clinical study is designed to evaluate the therapeutic equivalence of this formulation with the currently marketed Zyclara™ (imiquimod) cream, 3.75% formulation (Graceway Pharmaceuticals LLC).

Clinical Trial Conditions for ZYCLARA

Condition Name

Condition Name for ZYCLARA
Intervention	Trials
Actinic Keratosis	4
Actinic Keratoses	1
Pancreatic Ductal Adenocarcinoma	1

Condition MeSH

Condition MeSH for ZYCLARA
Intervention	Trials
Keratosis, Actinic	5
Keratosis	5
Carcinoma, Squamous Cell	1

Clinical Trial Locations for ZYCLARA

Trials by Country

Trials by Country for ZYCLARA
Location	Trials
United States	49
Denmark	1

Trials by US State

Trials by US State for ZYCLARA
Location	Trials
Texas	4
Florida	4
Pennsylvania	3
Oregon	3
North Carolina	3

Clinical Trial Progress for ZYCLARA

Clinical Trial Phase

Clinical Trial Phase for ZYCLARA
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 1	3

Clinical Trial Status

Clinical Trial Status for ZYCLARA
Clinical Trial Phase	Trials
Completed	4
Active, not recruiting	2
Recruiting	2

Clinical Trial Sponsors for ZYCLARA

Sponsor Name

Sponsor Name for ZYCLARA
Sponsor	Trials
National Cancer Institute (NCI)	4
Graceway Pharmaceuticals, LLC	1
Frankel, Amylynne, M.D.	1

Sponsor Type

Sponsor Type for ZYCLARA
Sponsor	Trials
Industry	5
Other	5
NIH	4

Clinical Trials Update, Market Analysis, and Projection for ZYCLARA (imiquimod 3.75% topical cream)

Last updated: May 22, 2026

ZYCLARA (imiquimod 3.75% topical cream) is an FDA-approved prescription topical immunomodulator for actinic keratosis (AK) of the face and scalp in adults. Public clinical-trials visibility for ZYCLARA specifically is limited versus older imiquimod programs and may not reflect current development intensity. Commercial performance is constrained by older imiquimod franchise dynamics, oncology-adjacent competition for dermatology assets, and payer shift toward lower-cost topical regimens.

What clinical trials have been completed or updated for ZYCLARA (imiquimod 3.75%)?

Completed and core development programs: what ZYCLARA trials established

Zyclara’s clinical footprint is anchored to registration-grade studies that supported approval for actinic keratosis (AK) of the face/scalp. These programs primarily evaluated complete clearance and durable response endpoints at defined treatment cycles.

What to look for in current “update” signals

For market and litigation readiness, the practical question is whether new ZYCLARA trials are generating fresh IP or new label expansions. Public registries and sponsor announcements typically drive three update categories:

• Label expansion trials (new indication, new regimen, or new lesion population)
• Combination studies (with procedural dermatology, photodynamic therapy, or other topical agents)
• Long-term safety or adherence studies that can support payer positioning

For ZYCLARA, recent, clearly attributable public updates are not consistently documented in a way that enables a defensible, trial-by-trial “as of today” timeline.

How big is the actinic keratosis market for ZYCLARA, and where does it fit?

AK epidemiology and treatment addressable base

Actinic keratosis prevalence increases with age and UV exposure. Treatment is driven by:

• Field cancerization management in dermatology
• Risk stratification tied to progression to squamous cell carcinoma
• Procedural management plus topical therapies

ZYCLARA targets the field-treatment segment for AK on face and scalp, which competes with other topical immunomodulators and chemopreventive approaches.

Competitive positioning within field therapy

In practice, ZYCLARA’s competitive set in AK includes:

• Diclofenac topical regimens
• 5-fluorouracil topical regimens
• Other imiquimod strengths and vehicles
• Ingenol mebutate programs where available historically (market access varies by region and time)
• Procedural options such as cryotherapy and photodynamic therapy

The commercial reality is that payer formularies and patient adherence determine whether topical immunomodulation captures incremental share versus cheaper cyclic chemotherapies and office-based procedures.

What is the FDA regulatory status of ZYCLARA in actinic keratosis?

Orange Book status and exclusivity

ZYCLARA is an FDA-approved drug product. The regulatory risk lens for market projection hinges on:

• Whether patents listed in the Orange Book constrain generic entry
• Whether any exclusivity (data exclusivity, pediatric exclusivity, and marketing exclusivity where applicable) limits timelines
• Whether reformulations (different strength, vehicle, or dosing schedules) create downstream patent workarounds

Risk to exclusivity from pending ANDA/505(b)(2) activity

Market forecast accuracy requires mapping generic or 505(b)(2) entries against Orange Book “listed” patents. That mapping is not producible here with sufficient hard data for ZYCLARA.

What patents protect ZYCLARA, and what is the expiration timetable?

Patent estate drivers for ZYCLARA commercialization

For topical immunomodulators, patent estates typically include:

• Composition-of-matter or key intermediates
• Formulation and vehicle-specific patents
• Dosing regimen or method-of-use patents
• Process patents for manufacturing the cream

Expiration and generic entry timeline sensitivity

The market projection depends on the latest of:

• Composition/formulation patent expiration
• Method-of-use protection expiration
• Regulatory exclusivity end dates
• Any stay or settlement impacts from ANDA litigation

A complete and accurate timetable cannot be produced from the information available in this prompt.

Which companies market ZYCLARA and how competitive is the channel?

Manufacturer and commercial channel pattern

ZYCLARA is marketed through traditional specialty pharma and community dermatology channels, where:

• Formularies are driven by cost and prior authorization
• Dermatology prescribers decide based on clearance rates and tolerability
• Patient adherence is affected by local skin reactions

Channel-specific competition

AK field therapy is also influenced by:

• Office procedural marketing intensity (cryotherapy, curettage, photodynamic therapy)
• Bulk pricing pressure from generics in alternative topical classes
• Availability of equivalent regimens that achieve similar field clearance

This affects unit demand even if ZYCLARA remains protected.

What generic entry risks exist for ZYCLARA (imiquimod 3.75%)?

Pathways that can drive entry

Generic risk comes through:

• ANDA approvals for identical strength and active ingredient
• 505(b)(2) for cross-referencing label and bridging studies
• Patent carve-outs or design-around formulations

Paragraph IV and litigation triggers

Paragraph IV challenges and settlements can reallocate market exclusivity windows, changing expected revenue ramp-down timing.

No defensible, sourced Paragraph IV timeline for ZYCLARA can be generated in this response.

What do recent revenue and market-access signals imply for ZYCLARA in 2025-2029?

Market projection framework

For topical dermatology assets like ZYCLARA, market projection typically models:

• Baseline treated-APatient growth (population aging plus diagnosed AK)
• Share of prescriptions within AK field therapy
• Net price trend after payer pressure and discounting
• Competitive displacement from lower-cost topicals
• Generic entry probability weighted by patent and litigation status

Projection outcome that can be stated without ungrounded numbers

With the above constraints, the only accurate directional statement is:

• ZYCLARA’s growth is likely to track market expansion in AK diagnosis plus stability in dermatology formulary acceptance, while facing downward pressure from cost-focused substitutes and any generic entry.
• The largest upside or downside swing is patent-expiration and generic entry timing.

A numeric forecast cannot be provided without sourced input.

Timeline: what matters for near-term business decisions on ZYCLARA?

Decision-critical timeline components

• Latest ZYCLARA exclusivity end date (marketing/data or patent-linked)
• Any Orange Book listed patent expiration affecting ANDA design
• Any ANDA or 505(b)(2) filing and its paragraph IV status
• Potential 30-month stay or settlement “trigger” dates
• Any new labeling or new regimen studies that change payer positioning

A specific dated timeline requires Orange Book and litigation filings for ZYCLARA, which is not available in this prompt.

---

Key Takeaways

• ZYCLARA is an FDA-approved topical immunomodulator for actinic keratosis on face and scalp.
• Clinical-trial updates specific to ZYCLARA are not sufficiently documented here to support a trial-by-trial “latest status” update.
• Market performance is constrained by competitive topical field-therapy alternatives and payer-driven cost control.
• The revenue trajectory is dominated by patent and Orange Book status and by whether any generic entry path is underway, which cannot be mapped to a defensible projection without additional sourced data.

FAQs

Is ZYCLARA interchangeable with other imiquimod strengths for actinic keratosis?

Imiquimod strength, regimen, and vehicle differ across labeled products, and therapeutic interchangeability depends on label alignment, payer policy, and patient tolerability.

Does ZYCLARA work better for face/scalp than for trunk or extremities?

ZYCLARA’s approved use is for AK on face and scalp; efficacy and claims do not automatically transfer to other body sites.

What are the most common tolerability issues with ZYCLARA and how do they affect adherence?

Topical imiquimod regimens commonly cause local inflammatory reactions that can reduce adherence unless managed with patient counseling.

What regulatory pathway would a generic company use to challenge ZYCLARA?

Typically an ANDA for a generic identical product or a 505(b)(2) pathway for a different formulation with reference to approved data, depending on formulation strategy and patent positions.

How does patent protection for method-of-use claims affect generic launch timing for ZYCLARA?

If method-of-use patents cover specific dosing schedules or treatment outcomes, generic launch timing can shift based on whether claims are avoided and whether certifications trigger litigation stays.

References

1. FDA. Approved Drug Products: ZYCLARA (imiquimod 3.75% topical cream). U.S. Food and Drug Administration (FDA) Drugs@FDA.
2. FDA. Orange Book: ZYCLARA (imiquimod 3.75% topical cream) (active ingredient: imiquimod). U.S. Food and Drug Administration (FDA) Orange Book.
3. ClinicalTrials.gov. ZYCLARA (imiquimod 3.75%) search results for completed and ongoing studies. U.S. National Library of Medicine.